99.25 USD
+0.00
0.00%
At close Jan 10, 4:00 PM EST
After hours
99.39
+0.14
0.14%
1 day
0.00%
5 days
0.49%
1 month
-1.73%
3 months
-9.28%
6 months
-22.03%
Year to date
0.08%
1 year
-16.50%
5 years
10.86%
10 years
59.31%
0
Funds holding %
of 6,810 funds
0
Analysts bullish %
of 9 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

8% more repeat investments, than reductions

Existing positions increased: 1,497 | Existing positions reduced: 1,389

7% more call options, than puts

Call options by funds: $1.98B | Put options by funds: $1.85B

9% less first-time investments, than exits

New positions opened: 145 | Existing positions closed: 159

2% less funds holding

Funds holding: 3,478 [Q2] → 3,416 (-62) [Q3]

3.03% less ownership

Funds ownership: 79.82% [Q2] → 76.78% (-3.03%) [Q3]

12% less capital invested

Capital invested by funds: $251B [Q2] → $221B (-$29.8B) [Q3]

42% less funds holding in top 10

Funds holding in top 10: 190 [Q2] → 111 (-79) [Q3]

Research analyst outlook

9 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$105
6%
upside
Avg. target
$118
19%
upside
High target
$130
31%
upside

9 analyst ratings

positive
44%
neutral
56%
negative
0%
UBS
Colin Bristow
18% 1-year accuracy
3 / 17 met price target
21%upside
$120
Buy
Maintained
8 Jan 2025
Truist Securities
Robyn Karnauskas
14% 1-year accuracy
4 / 28 met price target
11%upside
$110
Hold
Downgraded
8 Jan 2025
BMO Capital
Evan David Seigerman
22% 1-year accuracy
4 / 18 met price target
6%upside
$105
Market Perform
Downgraded
20 Dec 2024
B of A Securities
Tim Anderson
33% 1-year accuracy
2 / 6 met price target
22%upside
$121
Buy
Reinstated
10 Dec 2024
Guggenheim
Seamus Fernandez
58% 1-year accuracy
7 / 12 met price target
31%upside
$130
Buy
Maintained
6 Nov 2024

Financial journalist opinion

Based on 54 articles about MRK published over the past 30 days

Positive
Seeking Alpha
14 hours ago
3 Ideal Buys From 51 'Safer' Dividends In 100 January Barron's Sustainable Dogs
Calvert Research and Management's annual review identified the top 100 sustainable companies based on over 230 ESG performance indicators, including workplace diversity and greenhouse-gas emissions. Eight dividend-paying sustainable companies offer annual dividends from a $1K investment exceeding their single share prices, signaling potential buy opportunities. Analysts forecast net gains of 27.62% to 59.85% for top ESG companies by January 2026, with Regions Financial leading at an estimated 59.84%.
3 Ideal Buys From 51 'Safer' Dividends In 100 January Barron's Sustainable Dogs
Neutral
Business Wire
1 day ago
Atropos Health Collaborates with Merck for Rapid Evidence Generation to Accelerate Innovation for Life-Saving Treatments
PALO ALTO, Calif.--(BUSINESS WIRE)--Atropos Health, a pioneer in translating real-world clinical data into real-world evidence (RWE) for decision-making, today announced it will collaborate with Merck as a premier platform to generate RWE, replicate studies and produce rapid insights and analytics on real-world data (RWD). Through this collaboration, Atropos Health will enable rapid cohort creation, advanced analytics and publication-grade studies in less than 48 hours. As part of the agreement.
Atropos Health Collaborates with Merck for Rapid Evidence Generation to Accelerate Innovation for Life-Saving Treatments
Positive
CNBC
3 days ago
Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market
The FDA wrapped up 2024 with 50 new drug approvals, clearing a wave of long-awaited treatments. Meanwhile, Transcarent will take Accolade private.
Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market
Neutral
Barrons
3 days ago
There's a ‘Shadow' Over Biotech Stocks. Why It Isn‘t All Bad News.
UBS lowered its price targets for Pfizer, Merck, and Moderna stocks.
There's a ‘Shadow' Over Biotech Stocks. Why It Isn‘t All Bad News.
Neutral
Investors Business Daily
3 days ago
8 Stocks' Huge Profit Growth Is About To Knock Your Socks Off
Looking for some truly wowing profit growth from S&P 500 companies. A few are likely to knock your socks off.
8 Stocks' Huge Profit Growth Is About To Knock Your Socks Off
Positive
24/7 Wall Street
3 days ago
Merck Just Paid Investors: How Much Did They Receive?
Merck & Co. Inc. (NYSE: MRK) is rewarding its shareholders once again with a quarterly dividend of $0.81 per share, payable on Wednesday, Jan.
Merck Just Paid Investors: How Much Did They Receive?
Neutral
Business Wire
3 days ago
Merck's GARDASIL® Receives Expanded Approval for Males in China
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck's GARDASIL® Receives Expanded Approval for Males in China.
Merck's GARDASIL® Receives Expanded Approval for Males in China
Positive
Reuters
3 days ago
Merck says its HPV vaccine for men was approved by China's drug regulator
U.S. drugmaker Merck & Co said on Wednesday its human papillomavirus (HPV) vaccine for men has been approved by China's medical products administration.
Merck says its HPV vaccine for men was approved by China's drug regulator
Neutral
Zacks Investment Research
5 days ago
Merck (MRK) Rises Higher Than Market: Key Facts
Merck (MRK) closed at $99.72 in the latest trading session, marking a +0.59% move from the prior day.
Merck (MRK) Rises Higher Than Market: Key Facts
Positive
Reuters
5 days ago
China's WuXi Biologics to sell Ireland vaccine facility to Merck for $500 million
China's WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to Merck for about $500 million.
China's WuXi Biologics to sell Ireland vaccine facility to Merck for $500 million
Charts implemented using Lightweight Charts™